aDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA;
bCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya;
cInfectious Diseases Research Collaboration, Kampala, Uganda;
dDivision of Biostatistics and Epidemiology, School of Public Health, University of California, Berkeley, CA;
eDivision of Prevention Sciences, Department of Medicine, University of California, San Francisco, San Francisco, CA;
fDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA; and
gDepartment of Medicine, Makerere University, Kampala, Uganda.
Correspondence to: Sarah B. Puryear, MD, MPH, Division of HIV, Infectious Diseases and Global Medicine, University of California, 995 Potrero Avenue, Ward 84, San Francisco, CA 94110 (e-mail: [email protected])
Supported by the Division of AIDS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) (UM1AI068636 and U01AI099959, D.V.H.) and in part by the President's Emergency Plan For AIDS Relief and Gilead Sciences, which provided tenofovir–emtricitabine (Truvada) in kind. Additional funding by the National Institute on Alcohol Abuse and Alcoholism (K23 AA029045, SBP; K24 AA022586, J.A.H.) of the NIH.
Conference on Retroviruses and Opportunistic Infections (CROI); Boston, Massachusetts, USA/Virtual; March 8–11, 2020.
The authors have no funding or conflicts of interest to disclose.
